Compare BMNP & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BMNP | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2022 | 2021 |
| Metric | BMNP | ERNAW |
|---|---|---|
| Price | $94.10 | $0.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 50.3K | 21.7K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19228.57 | 31.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,310,348.00 | $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 413.01 | N/A |
| 52 Week Low | $79.73 | $0.02 |
| 52 Week High | $93.75 | $0.23 |
| Indicator | BMNP | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 81.81 | 52.88 |
| Support Level | $85.13 | $0.03 |
| Resistance Level | N/A | $0.10 |
| Average True Range (ATR) | 1.53 | 0.02 |
| MACD | 0.32 | 0.00 |
| Stochastic Oscillator | 92.44 | 69.21 |
BitMine Immersion Technologies Inc is a Bitcoin and Ethereum Network Company with a focus on the accumulation of Crypto for long term investment, whether acquired by its Bitcoin mining operations or from the proceeds of capital raising transactions. Company business lines include Bitcoin Mining, Synthetic Bitcoin mining through involvement in Bitcoin mining, hashrate as a financial product, offering advisory and mining services to companies interested in earning Bitcoin denominated revenues, and general Bitcoin advisory to public companies. BitMine's operations are located in low-cost energy regions in Trinidad; Pecos, Texas; and Silverton, Texas.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.